Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

State highlights: Md. submits plan to tie overhaul hospital charges to state's economy

A selection of health policy stories from Maryland, California, Missouri and Florida.

15 Oct 2013

Teva gets FDA approval for generic version of TOBI in US

Teva Pharmaceutical Industries Ltd. announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI (Tobramycin Inhalation Solution USP) in the United States.

15 Oct 2013

First Edition: October 14, 2013

Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.

14 Oct 2013

Viewpoints: U.S. 'designed for stalemate'; tea party's last stand?; 'war over Obamacare' not over

Though the big social insurance programs are still running, many federal programs that directly target those in the most need are either empty or running on fumes. ... The growth of the modern state is tied to the awareness of public issues in health and the need to address them.

8 Oct 2013

inVentiv Health Clinical releases new tool to connect physicians participating in late-stage research

inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.

24 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

Walgreens’ August sales increased by 5.6% to $6.17 billion

Walgreens had August sales of $6.17 billion, an increase of 5.6 percent from $5.84 billion for the same month in fiscal 2012.

5 Sep 2013

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Teva Pharmaceutical Industries Ltd. and Perrigo Company today announced the launch of the generic equivalent to Temodar (temozolomide).

13 Aug 2013

Brand-name and generic drug makers take fight to states

The battle concerns state notification laws that would require pharmacists to notify doctors and patients when they substitute generic versions of drugs derived from living organisms known as biologics.

12 Aug 2013

CVS Caremark net revenues increase 1.7% in Q2 2013

CVS Caremark Corporation today announced operating results for the three months ended June 30, 2013.

6 Aug 2013

PharMerica reports net income of $10.2 million for Q2 2013

PharMerica Corporation, a national provider of pharmacy services, today reported its financial results for the second quarter and six months ended June 30, 2013.

2 Aug 2013

Teva, Lonza decide to discontinue biosimilars collaboration

Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.

25 Jul 2013

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

High Court: Feds can sue pharmaceutical companies over deals to delay generic drug sales

The Supreme Court ruled Monday that the Federal Trade Commission can challenge name brand drug makers for potential antitrust violations.

19 Jun 2013

First Edition: June 18, 2013

Today's headlines include reports about a new publicity push in support of the health law.

18 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Viewpoints: Medicaid expansion 'makes sense'; Budget cuts hurt Alzheimer's research; Lack of transparency in generic Rx prices

The numbers in the Rand study ... should not be a surprise to people who have been paying attention. Numerous studies now, including in Missouri, have pointed to the simple reality of the policy implications of the ACA to argue for Medicaid expansion.

12 Jun 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Subsidiary of Indian drug firm pleads guilty, agrees to $500 million penalty

A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S.

15 May 2013